• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by KALA BIO Inc. (Amendment)

    10/18/23 4:04:57 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KALA alert in real time by email
    SC 13D/A 1 d559985dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)

     

     

    KALA BIO, INC.

    (Name of Issuer)

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

    483119103

    (CUSIP Number)

    Patrick G. Enright

    Managing Member

    Longitude Capital Partners II, LLC

    2740 Sand Hill Road, 2nd Floor

    Menlo Park, CA 94025

    (650) 854-5700

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    May 1, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on following pages)

     

     

     


    CUSIP No. 483119103       13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Longitude Capital Partners II, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     (a) ☐  (b) ☒

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     OO (1)

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     57,541 (2)

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     57,541 (2)

     11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     57,541 (2)

     12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

     13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     2.3% (3)

     14  

     TYPE OF REPORTING PERSON (see instructions)

     

     OO

     

    1

    The securities over which the Reporting Persons have shared voting and dispositive power were purchased using investment funds from investors of Longitude Venture Partners II, L.P. (“LVPII”).

    2

    All shares are held of record by LVPII. Longitude Capital Partners II, LLC (“LCPII”) is the general partner of LVPII and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPII and may be deemed to share voting, investment and dispositive power with respect to these securities.

    3

    The percentage was calculated based on 2,542,716 outstanding shares of Common Stock as of August 3, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the “Commission”) on August 4, 2023 (the “Form 10-Q”).


    CUSIP No. 483119103       13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Longitude Venture Partners II, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     (a) ☐  (b) ☒

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     OO (1)

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     57,541 (2)

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     57,541 (2)

     11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     57,541 (2)

     12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

     13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     2.3% (3)

     14  

     TYPE OF REPORTING PERSON (see instructions)

     

     PN

     

    1

    The securities over which the Reporting Persons have shared voting and dispositive power were purchased using investment funds from investors of LVPII.

    2

    All shares are held of record by LVPII. LCPII is the general partner of LVPII and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPII and may be deemed to share voting, investment and dispositive power with respect to these securities.

    3

    The percentage was calculated based on 2,542,716 outstanding shares of Common Stock as of August 3, 2023, as reported by the Issuer in the Form 10-Q.


    CUSIP No. 483119103       13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Longitude Capital Partners IV, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     (a) ☐  (b) ☒

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     OO (1)

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     50,698 (2)

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     50,698 (2)

     11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     50,698 (2)

     12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

     13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     2.0% (3)

     14  

     TYPE OF REPORTING PERSON (see instructions)

     

     OO

     

    1

    The securities over which the Reporting Persons have shared voting and dispositive power were purchased using investment funds from investors of Longitude Venture Partners IV, L.P. (“LVPIV”).

    2

    All shares are held of record by LVPIV. Longitude Capital Partners IV, LLC (“LCPIV”) is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPIV and may be deemed to share voting, investment and dispositive power with respect to these securities.

    3

    The percentage was calculated based on 2,542,716 outstanding shares of Common Stock as of August 3, 2023, as reported by the Issuer in the Form 10-Q.


    CUSIP No. 483119103       13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Longitude Venture Partners IV, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     (a) ☐  (b) ☒

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     OO (1)

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     50,698 (2)

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     50,698 (2)

     11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     50,698 (2)

     12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

     13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     2.0% (3)

     14  

     TYPE OF REPORTING PERSON (see instructions)

     

     PN

     

    1

    The securities over which the Reporting Persons have shared voting and dispositive power were purchased using investment funds from investors of LVPIV.

    2

    All shares are held of record by LVPIV. LCPIV is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPIV and may be deemed to share voting, investment and dispositive power with respect to these securities.

    3

    The percentage was calculated based on 2,542,716 outstanding shares of Common Stock as of August 3, 2023, as reported by the Issuer in the Form 10-Q.


    CUSIP No. 483119103       13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Patrick G. Enright

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     (a) ☐  (b) ☒

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     OO (1)

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     108,239 (2)

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     108,239 (2)

     11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     108,239 (2)

     12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

     13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     4.3% (3)

     14  

     TYPE OF REPORTING PERSON (see instructions)

     

     IN

     

    1

    The securities over which the Reporting Person has shared voting and dispositive power were purchased using investment funds from investors of LVPII and LVPIV.

    2

    Consists of (a) 57,541 outstanding shares of Common Stock held of record by LVPII and (b) 50,698 outstanding shares of Common Stock held of record by LVPIV. LCPIV is the general partner of LVPIV and LCPII is the general partner of LVPII, and may each be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPIV and LCPII and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    3

    The percentage was calculated based on 2,542,716 outstanding shares of Common Stock as of August 3, 2023, as reported by the Issuer in the Form 10-Q.


    CUSIP No. 483119103       13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Juliet Tammenoms Bakker

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     (a) ☐  (b) ☒

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     OO (1)

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     108,239 (2)

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     108,239 (2)

     11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     108,239 (2)

     12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

     13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     4.3% (3)

     14  

     TYPE OF REPORTING PERSON (see instructions)

     

     IN

     

    1

    The securities over which the Reporting Persons have shared voting and dispositive power were purchased using investment funds from investors of LVPII and LVPIV.

    2

    Consists of (a) 57,541 outstanding shares of Common Stock held of record by LVPII and (b) 50,698 outstanding shares of Common Stock held of record by LVPIV. LCPIV is the general partner of LVPIV and LCPII is the general partner of LVPII, and may each be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPIV and LCPII and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    3

    The percentage was calculated based on 2,542,716 outstanding shares of Common Stock as of August 3, 2023, as reported by the Issuer in the Form 10-Q.


    CUSIP No. 483119103       13D

     

    Explanatory Note:

    This joint statement on Schedule 13D/A (this “Statement”) is filed with respect to the common stock, par value $0.001 per share (“Common Stock”), of Kala Bio, Inc., a Delaware corporation (the “Issuer”).

    Item 2. Identity and Background.

    (a) This Amendment No. 3 (this “Amendment”) amends and supplements the Schedule 13D originally filed with the Commission on October 12, 2018, as amended by Amendment No. 1 filed with the Commission on March 23, 2020 (“Amendment No. 1”), and Amendment No. 2 filed with the with the Commission on February 14, 2023 (collectively, the “Original Schedule 13D”). This Amendment is being filed to update the aggregate percentage of the Issuer’s Common Stock owned by the Reporting Persons due to dilution caused by, among other things, the Issuer’s sales of additional shares of its Common Stock from time to time since the date of the filing of the Original Schedule 13D and not in connection with a disposition of any shares by the Reporting Persons. Such dilution resulted in a decrease of over one percent (1%) in the aggregate percentage ownership reported by the Reporting Persons in the Original Schedule 13D. Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13D.

    Item 5. Interest in Securities of the Issuer.

    Item 5 of the Original Schedule 13D is hereby amended to add the following language:

    (a) and (b) See Items 7-11 of the cover pages of this Amendment and Item 2 above.

    (e) On May 1, 2023, each of the Reporting Persons ceased to be the beneficial owner of more than five percent of the outstanding shares of Common Stock.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: October 18, 2023.

     

    LONGITUDE VENTURE PARTNERS IV, L.P.
    By:   LONGITUDE CAPITAL PARTNERS IV, LLC
    Its:   General Partner
    By:   /s/ Cristiana Blauth Oliveira
     

    Cristiana Blauth Oliveira, Authorized Signatory

    LONGITUDE CAPITAL PARTNERS IV, LLC
    By:   /s/ Cristiana Blauth Oliveira
     

    Cristiana Blauth Oliveira, Authorized Signatory

    LONGITUDE VENTURE PARTNERS II, L.P.
    By:   LONGITUDE CAPITAL PARTNERS II, LLC
    Its:   General Partner
    By:   /s/ Cristiana Blauth Oliveira
     

    Cristiana Blauth Oliveira, Authorized Signatory

    LONGITUDE CAPITAL PARTNERS II, LLC
    By:   /s/ Cristiana Blauth Oliveira
     

    Cristiana Blauth Oliveira, Authorized Signatory

    /s/ Patrick G. Enright

    Patrick G. Enright

    /s/ Juliet Tammenoms Bakker

    Juliet Tammenoms Bakker

    Get the next $KALA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KALA

    DatePrice TargetRatingAnalyst
    3/30/2022Neutral → Underweight
    JP Morgan
    8/6/2021$14.00 → $11.00Buy
    HC Wainwright & Co.
    8/6/2021Overweight → Neutral
    JP Morgan
    More analyst ratings

    $KALA
    Financials

    Live finance-specific insights

    See more
    • Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

      ARLINGTON, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA) ("Kala" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on August 29, 2022. The shares of Series D Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on August 30, 2022. The

      8/18/22 4:01:00 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

      -- Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 ---- Received $60M Upfront Payment from Sale of EYSUVIS® and INVELTYS® to Alcon Inc. and Significantly Reduced Operating Expenses, Extending Cash Runway into 2Q 2024 -- -- Conference Call and Webcast at 8:00 a.m. ET -- ARLINGTON, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today reported financial results for the second quarter ended June 30, 2022 and prov

      8/11/22 7:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kala Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call

      ARLINGTON, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will report second quarter 2022 financial results on Thursday, August 11, 2022. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET. The dial-in number to access the conference call is 800-715-9871 using the conference ID 9372651. To access a live webcast and subsequent archived recording of the call, please visit the "Presentations" se

      8/8/22 9:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Officer Bazemore Todd

      4 - KALA BIO, Inc. (0001479419) (Issuer)

      3/10/25 8:00:08 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 4 filed by Officer Brazzell Romulus K

      4/A - KALA BIO, Inc. (0001479419) (Issuer)

      1/10/25 8:00:36 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Bazemore Todd was granted 10,100 shares and sold $15,207 worth of shares (1,993 units at $7.63), increasing direct ownership by 10% to 91,147 units (SEC Form 4)

      4 - KALA BIO, Inc. (0001479419) (Issuer)

      1/7/25 8:14:03 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      -- Randomized 87 patients to date in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED) -- -- Continuing enrollment into 2Q25; currently targeting topline data in 3Q25 -- -- Raised $10.75 million in private placement financing with participation from SR One, Cormorant Asset Management, Woodline Partners and another life sciences-focused investor -- -- Cash resources of $51.2 million as of December 31, 2024, expected to fund operations into 1Q 2026 -- ARLINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies

      3/31/25 8:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KALA BIO to Present at TD Cowen 45th Annual Health Care Conference

      ARLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the TD Cowen 45th Annual Health Care Conference being held in Boston, MA on Wednesday, March 5, 2025 at 11:50 a.m. ET. Management will also be available for one-on-one meetings on Wednesday, March 5, 2025. To access the webcast and subsequent archived recording of the presentation, please visit the "Presentations" section of the KALA website at www.kalarx.com. About KALA BIO, Inc. K

      2/26/25 8:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KALA BIO Announces Chief Executive Officer Transition

      ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the resignation of Chief Executive Officer (CEO) Mark Iwicki, and the appointment of Todd Bazemore, KALA's President and Chief Operating Officer, as interim CEO, effective immediately. Mr. Iwicki will continue to serve as Chair of the Board of Directors of KALA following the transition. Mr. Bazemore has served as KALA's President since December 2021 and as KALA's Chief Operating Officer since November 2017. Mr. Iwicki stated,

      2/12/25 8:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALA
    SEC Filings

    See more

    $KALA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $KALA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • KALA BIO Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - KALA BIO, Inc. (0001479419) (Filer)

      4/11/25 4:09:11 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by KALA BIO Inc.

      424B5 - KALA BIO, Inc. (0001479419) (Filer)

      3/31/25 8:45:34 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by KALA BIO Inc.

      10-K - KALA BIO, Inc. (0001479419) (Filer)

      3/31/25 8:03:08 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by KALA BIO Inc.

      SC 13G - KALA BIO, Inc. (0001479419) (Subject)

      11/14/24 4:49:42 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by KALA BIO Inc.

      SC 13D - KALA BIO, Inc. (0001479419) (Subject)

      7/8/24 8:54:55 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by KALA BIO Inc.

      SC 13D - KALA BIO, Inc. (0001479419) (Subject)

      6/28/24 4:11:51 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Baker Bros. Advisors Lp bought $2,000,000 worth of shares (310,559 units at $6.44) (SEC Form 4)

      4 - KALA BIO, Inc. (0001479419) (Issuer)

      12/31/24 4:00:18 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kala Pharmaceuticals downgraded by JP Morgan

      JP Morgan downgraded Kala Pharmaceuticals from Neutral to Underweight

      3/30/22 7:39:31 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Kala Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Kala Pharmaceuticals with a rating of Buy and set a new price target of $11.00 from $14.00 previously

      8/6/21 6:36:47 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kala Pharmaceuticals downgraded by JP Morgan

      JP Morgan downgraded Kala Pharmaceuticals from Overweight to Neutral

      8/6/21 5:55:07 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALA
    Leadership Updates

    Live Leadership Updates

    See more
    • KALA BIO Announces Chief Executive Officer Transition

      ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the resignation of Chief Executive Officer (CEO) Mark Iwicki, and the appointment of Todd Bazemore, KALA's President and Chief Operating Officer, as interim CEO, effective immediately. Mr. Iwicki will continue to serve as Chair of the Board of Directors of KALA following the transition. Mr. Bazemore has served as KALA's President since December 2021 and as KALA's Chief Operating Officer since November 2017. Mr. Iwicki stated,

      2/12/25 8:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

      -- Announced positive data from initial safety portion of CHASE Phase 2b clinical trial of KPI-012; now enrolling primary safety and efficacy portion of trial, with topline data targeted in 1Q 2024 ---- Received FDA Fast Track designation for KPI-012 for the treatment of PCED ---- Strengthened clinical R&D team with appointment of Dr. Francis Mah as Chief Medical Advisor – -- Awarded $15 million grant from CIRM to support the KPI-012 PCED program -- ARLINGTON, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and sever

      5/9/23 8:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor

      ARLINGTON, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the appointment of Francis Mah, M.D., as Chief Medical Advisor. In this newly established role, Dr. Mah will provide support for Kala's clinical development and medical activities and will play a key role in interactions with eye care professionals. Dr. Mah will serve in this role on a part time basis while continuing his ongoing position as Director of Cornea and External Disease and the Co-Director, Refractive Su

      3/29/23 8:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care